New look on the use of sodium escinate in patients with post-COVID conditions
DOI: 10.32364/2587-6821-2022-6-1-33-38
Z.Kh. Shugushev1,2, A.A. Akulova2
1Russian University of Peoples’ Friendship, Moscow, Russian Federation
2Central Clinical Hospital RZD-Meditsina, Moscow, Russian Federation
The emergence of the COVID-19 infection associated with multisystem disorders, long-term-complications (post-COVID conditions), low productivity and reduced quality of life, the lack of a unified treatment resulted to the search of novel agents and expansion of indication for use of pre-existing medications. Escine is an active ingredient of Aesculus hippocastanum (horse chestnut) which is well-known in the phlebological pharmaceutical market. This paper reviews recent pharmacological and clinical data on anti-edematous, anti-inflammatory, and antioxidant effects of sodium escinate in post-COVID conditions. The anti-inflammatory and antiviral effects of sodium escinate involve inhibiting the secretion of proinflammatory cytokines (including tumor necrosis factor α and interleukin 1β) by LPS-induced RAW264.7 macrophages. In Russia, escine is a component of a combined formulation based on horse chestnut seed extract and thiamine (vitamin B1). Given efficacy of sodium escinate (based on the results of in vitro and in vivo experimental studies) and its antiviral and anti-inflammatory properties, this agent can be prescribed for the COVID-19 complications.
Keywords: sodium escinate, post-COVID conditions, anti-inflammatory effects, phlebological agent, SARS-CoV-2.
For citation: Shugushev Z.Kh., Akulova A.A. New look on the use of sodium escinate in patients with post-COVID conditions. Russian Medical Inquiry. 2022;6(1):33–38 (in Russ.). DOI: 10.32364/2587-6821-2022-6-1-33-38.
Acknowledgments
The authors and Editorial Board are grateful to ESPARMA GmbH for providing full-text foreign articles required to write the review.
About the authors:
Zaurbek Kh. Shugushev — Dr. Sc. (Med.), Head of the Department of Cardiovascular Surgery, Russian University of Peoples’ Friendship; 6, Miklukho-Maklaya str., Moscow, 117198, Russian Federation; Chief Cardiologist of the Central Directorate of Healthcare, Head of the Center of Cardiovascular Disorders, Head of the Department, Central Clinical Hospital RZD-Meditsina; 84, Volokolamskoe road, Moscow, 125367, Russian Federation; ORCID iD 0000-0002-5335-5062.
Anastasiya A. Akulova — Head of the Department of Vascular Surgery, Central Clinical Hospital RZD-Meditsina; 84, Volokolamskoe road, Moscow, 125367, Russian Federation; ORCID iD 0000-0003-2820-2432.
Contact information: Anastasiya A. Akulova, e-mail:
akulovanastya@gmail.com.
Financial Disclosure: no authors have a financial or property interest in any material or method mentioned.
There is no conflict of interests.
Received 11.01.2022.
Revised 03.02.2022.
Accepted 01.03.2022.
2. Xin W., Zhang L., Sun F. et al. Escin exerts synergistic antiinflammatory effects with low doses of glucocorticoids in vivo and in vitro. Phytomedicine. 2011;18(4):272–277. DOI: 10.1016/j.phymed.2010.08.013.
3. ICD-10 — International Statistical Classification of Diseases and Related Health Problems 10 revision. (Electronic resource.) URL: https://mkb-10.com/index.php?pid=23014 (access date: 10.12.2021).
4. Pavli A., Theodoridou M., Maltezou H.C. Post-COVID syndrome: Incidence, clinical spectrum, and challenges for primary healthcare professionals. Arch Med Res. 2021;52(6):575–581. DOI: 10.1016/j.arcmed.2021.03.010.
5. Alemanno F., Houdayer E., Parma A. et al. COVID-19 cognitive deficits after respiratory assistance in the subacute phase: A COVID- rehabilitation unit experience. PLoS One. 2021;16: e0246590. DOI: 10.1371/journal.pone. 0246590.
6. Simmonds P., Williams S., Harvala H. Understanding the outcomes of COVID-19 — does the current model of an acute respiratory infection really fit? J Gen Virol. 2021;102(3):10–15. DOI: 10.1099/jgv.0.001545.
7. Ursini F., Ciaffi J., Mancarella L. et al. Fibromyalgia: a new facet of the post-COVID-19 syndrome spectrum? Results from a web-based survey. RMD Open. 2021;7(3):e001735. DOI: 10.1136/rmdopen-2021-001735.
8. Li Y., Samuvel D.J., Sundararaj K.P. et al. IL6 and high glucose synergistically upregulate MMP1 expression by U937 mononuclear phagocytes via ERK1/2 and JNK pathways and cJun. J Cell Bioch. 2010;110(1):248–259. DOI: 10.1002/jcb.22532.
9. Guo W., Li M., Dong Y. et al. Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes Metab Res Rev. 2020;e3319. DOI: 10.1002/dmrr.3319.
10. Lorenz D., Marek M.L. The active therapeutic principle of horse chestnut (Aesculus hippocastanum). Part 1. Classification of the active substance Arzneimittelforschung. 1960;10:263–272 (in German).
11. Pietta P., Mauri P.J. High-performance liquid chromatographic analysis of β-escin. J Chromatogr. 1989;478:259–263. DOI: 10.1016/S0021-9673(01)84394-6.
12. European Medicines Agency. Assessment report on Aesculus Hipoocastanum L., semen; 2009. (Electronic resource.) URL: http://www.ema.europa.eu/documents/herbal-report/assessment-report-aesculus-hippo castanum-l-semenen (access date: 30.11.2021).
13. Wu C.Y., Jan J.T., Ma S.H. et al. Small molecules targeting severe acute respiratory syndrome human coronavirus. Proc Natl Acad Sci USA. 2004;101(27):10012–10017. DOI: 10.1073/pnas.0403596101.
14. Salinas F.M., Vazquez L., Gentilini M.V. et al. Aesculus hippocastanum L. seed extract shows virucidal and antiviral activities against respiratory syncytial virus (RSV) and reduces lung inflammation in vivo. Antiviral Res. 2019;164:1–11. DOI: 10.1016/j.antiviral.2019.01.018.
15. Michelini F.M., Alche L.E., Bueno C.A. Virucidal, antiviral and immunomodulatory activities of beta-escin and Aesculus hippocastanum extract. J Pharm Pharmacol. 2018;70(11):1561–1571. DOI: 10.1111/jphp.13002.
16. Wang B., Mao X., Zhu J. beta-aescin alleviates acute lung injury induced by lipopolysaccharide by inhibiting lipid peroxidation and inflammation in mice. Chinese J Cell Mol Immunol. 2018;34(7):600–604.
17. Wang Z., Zhao F., Jiang G. et al. Clinical study of hyperthermia combined with Aescinate Sodium for Injection in treating pneumonia-like pleural effusion. China Med Herald. 2019;16(8):113–116.
18. Zhang K., Lu Y., Li D., Liang S. The effect of Shunqi Huoxue decoction combined with β-sodium aescinate in the treatment of acute lung injury caused by thoracic trauma and influences on serum ferritin superoxide dismutase and lung function. Shaanxi J Tradi Chinese Med. 2018;39(12):1798–1801.
19. Liu W., Liang Y., Wang L. et al. Effect of β-sodium aescinate on 35 cases of pulmonary contusion. Hebei Med J. 2009;31(22):3074–3075.
20. Tang S., Gong F., Wu Z. Clinical trial of β-sodium aescinate injection in the treatment of chronic obstructive pulmonary disease complicated with pneumocardial disease and heart failure. Chin J Clin Pharmacol. 2019;35(21):2651–2654.
21. Gallelli L. Escin: a review of its anti-edematous, anti-inflammatory, and venotonic properties. Drug Des Devel Ther. 2019;13:3425–3437. DOI: 10.2147/DDDT.S207720.
22. Шемерянкина Т.Б., Жарова О.Г., Сокольская Т.А. и др. Совершен- ствование методов контроля и критериев стандартизации качества семян и сухого очищенного экстракта из семян конского каштана обыкновенного (Aesculus hippocastanum L.) Вопросы биологической, медицинской, фармацевтической химии. 2012;3:3–11.
[Shemeryankina T.B., Zharova O.G., Sokolskaya T.A. Improvement of control methods and criteria for standardization of the quality of seeds and dry purified extract from the seeds of horse chestnut (Aesculus hippocastanum L.). Problems of biological, medical and pharmaceutical chemistry. 2012;3:3–11 (in Russ.)].
23. Богачев В.Ю., Болдин Б.В., Дженина О.В. Эскузан: фармакология, фармакокинетика и терапевтические характеристики. Амбулаторная хирургия. 2019;1–2:19–25. DOI: 10.21518/1995-1477-2019-1-2-19-25. [Bogachev V.Yu., Boldin B.V., Jenina O.V. Aescusan: pharmacology, pharmacokinetics and therapeutic characteristics. Ambulatornaya khirurgiya. 2019;1–2:19–25 (in Russ.)]. DOI: 10.21518/1995-1477-2019-1- 2-19-25.
24. Демехова М.Ю. Гормональная контрацепция и венозные тром- боэмболические осложнения у женщин. РМЖ. Мать и дитя. 2017;25(12):884–888.
[Demekhova M.Yu. Hormonal contraception and venous thromboembolic complications in women. Russian Journal of Woman and Child Health. 2017;25(12):884–888 (in Russ.)].
This work is licensed under a Creative Commons «Attribution» 4.0 License.
Распечатать